{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:49:51Z","timestamp":1794365391712,"version":"4.9.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To compare the incidence of abdominal pain, dyspepsia and\/or nausea associated with valdecoxib, nonspecific nonsteroidal anti\u2010inflammatory drugs and placebo in patients with rheumatoid arthritis and osteoarthritis.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002Data from five randomized, double\u2010blind 12\u2010week trials were pooled. Independent risk factors for abdominal pain, dyspepsia and\/or nausea were also determined.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002The final analysis consisted of 4394 patients. Nonspecific nonsteroidal anti\u2010inflammatory drug users (<jats:italic>n<\/jats:italic>\u2003= 1185) received naproxen 1000\u2003mg\/day (<jats:italic>n<\/jats:italic>\u2003=\u2003766), ibuprofen 2400\u2003mg\/day (<jats:italic>n<\/jats:italic>\u2003=\u2003207) or diclofenac sodium 150\u2003mg\/day (<jats:italic>n<\/jats:italic>\u2003=\u2003212). Valdecoxib users received 10\u2003mg\/day (<jats:italic>n<\/jats:italic>\u2003=\u2003955), 20\u2003mg\/day (<jats:italic>n<\/jats:italic>\u2003=\u2003851) or 40\u2003mg\/day (<jats:italic>n<\/jats:italic>\u2003=\u2003430). A total of 973 patients received placebo. The nonspecific nonsteroidal anti\u2010inflammatory drug group was most likely to report abdominal pain or dyspepsia, while the placebo group reported the highest incidence of nausea. The most important risk factors for abdominal pain, dyspepsia and\/or nausea were nonspecific nonsteroidal anti\u2010inflammatory drug use, gastrointestinal history of nonspecific nonsteroidal anti\u2010inflammatory drug\u2010related intolerance or gastroduodenal ulcers, osteoarthritis diagnosis, female gender and age &lt;65\u2003years.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> :\u2002This pooled analysis demonstrates a clear decrease in dyspepsia and an improvement in upper gastrointestinal tolerability for patients with osteoarthritis and rheumatoid arthritis taking valdecoxib, even at supratherapeutic doses, compared with those taking nonspecific nonsteroidal anti\u2010inflammatory drugs over 12\u2003weeks.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02383.x","type":"journal-article","created":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T09:48:39Z","timestamp":1109670519000},"page":"591-598","source":"Crossref","is-referenced-by-count":27,"title":["Meta\u2010analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase\u20102\u2010specific inhibitor, compared with nonspecific nonsteroidal anti\u2010inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis"],"prefix":"10.1111","volume":"21","author":[{"given":"G. M.","family":"Eisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. B.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Rublee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00207-6"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198904000-00009"},{"key":"e_1_2_6_4_2","first-page":"2088","article-title":"Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis: how physicians manage treatment failures","volume":"25","author":"Spencer\u2010Green G","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.11.1095"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02332-6"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/030097401750065265"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-4-199508150-00001"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/archinte.1996.00440130066007","article-title":"Gastrointestinal tract complications of nonsteroidal anti\u2010inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study","volume":"156","author":"Singh G","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.9.1008"},{"key":"e_1_2_6_13_2","first-page":"530","article-title":"Randomized placebo\u2010controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis","volume":"51","author":"Kivitz A","year":"2002","journal-title":"J Fam Pract"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2001.0510"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg359"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm990577v"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2004.10.001"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01650.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02118.x"},{"issue":"9","key":"e_1_2_6_20_2","first-page":"S335","article-title":"Valdecoxib provides improved efficacy in patients with rheumatoid arthritis, even when administered concomitantly to patients already taking DMARDs or low\u2010dose corticosteroids [abstract]","volume":"46","author":"Weaver A","year":"2002","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200210000-00011"},{"key":"e_1_2_6_22_2","unstructured":"Adverse Reaction Terminology WHO\u2010ART.Uppsala Monitoring Centre Products & Services. Available at:http:\/\/www.umc\u2010products.com\/DynPage.aspx?id=4918&mn=1107. Accessed 7 September2004."},{"key":"e_1_2_6_23_2","volume-title":"Statistical Methods for Survival Data Analysis","author":"Lee ET.","year":"1992"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11192"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.37217"},{"key":"e_1_2_6_26_2","first-page":"1876","article-title":"Upper gastrointestinal tolerability of celecoxib, a COX\u20102 specific inhibitor, compared to naproxen and placebo","volume":"27","author":"Bensen WG","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01219.x"},{"key":"e_1_2_6_28_2","first-page":"35","article-title":"Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis","volume":"20","author":"McKenna F","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.19.2998"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02383.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02383.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:07:44Z","timestamp":1697231264000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02383.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02383.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02383.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}